Document
Abstract
RDF description of HSV-TK engineered donor lymphocytes add-backs reduce late mortality and improve survival of high risk acute leukemia after haplo-HSCT: Results of a phase II multicenter trial. - http://irises.unisr.it/resource/item/16362
HSV-TK engineered donor lymphocytes add-backs reduce late mortality and improve survival of high risk acute leukemia after haplo-HSCT: Results of a phase II multicenter trial.
Generically Dependent Continuant
Information Content Entity